Perritt Capital Management Inc Has $637,000 Stock Holdings in biote Corp. (NASDAQ:BTMD)

Perritt Capital Management Inc raised its stake in shares of biote Corp. (NASDAQ:BTMD) by 41.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 103,150 shares of the company’s stock after purchasing an additional 30,000 shares during the period. Perritt Capital Management Inc’s holdings in biote were worth $637,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Jane Street Group LLC boosted its position in biote by 24.7% during the third quarter. Jane Street Group LLC now owns 16,873 shares of the company’s stock valued at $94,000 after purchasing an additional 3,342 shares during the last quarter. Rhumbline Advisers raised its stake in shares of biote by 11.6% during the 4th quarter. Rhumbline Advisers now owns 37,688 shares of the company’s stock worth $233,000 after purchasing an additional 3,920 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of biote by 7.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 75,738 shares of the company’s stock valued at $468,000 after buying an additional 5,215 shares during the last quarter. Sei Investments Co. grew its stake in shares of biote by 56.4% in the 4th quarter. Sei Investments Co. now owns 18,321 shares of the company’s stock valued at $113,000 after buying an additional 6,605 shares in the last quarter. Finally, MetLife Investment Management LLC increased its holdings in biote by 129.1% in the third quarter. MetLife Investment Management LLC now owns 16,582 shares of the company’s stock worth $93,000 after buying an additional 9,343 shares during the last quarter. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at biote

In other news, Director Stephen Mark Cone acquired 38,104 shares of biote stock in a transaction dated Monday, March 17th. The stock was acquired at an average cost of $3.88 per share, for a total transaction of $147,843.52. Following the completion of the purchase, the director now owns 160,829 shares of the company’s stock, valued at $624,016.52. This represents a 31.05 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Guines Llc bought 750,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was purchased at an average price of $3.22 per share, for a total transaction of $2,415,000.00. Following the completion of the purchase, the insider now directly owns 3,820,938 shares in the company, valued at $12,303,420.36. The trade was a 24.42 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 788,204 shares of company stock worth $2,563,218. 13.90% of the stock is owned by corporate insiders.

biote Trading Up 9.0 %

Shares of NASDAQ:BTMD opened at $3.63 on Wednesday. The stock has a market capitalization of $198.60 million, a PE ratio of 13.96 and a beta of 1.07. biote Corp. has a 1 year low of $3.04 and a 1 year high of $8.44. The firm has a fifty day moving average price of $4.48 and a 200 day moving average price of $5.36.

Analyst Ratings Changes

Separately, Craig Hallum reduced their target price on shares of biote from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, March 13th.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.